Quest Diagnostics Incorporated: insider trading
1,858 trades by 44 directors, officers and 10% owners since 2010, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$47.4 M
41 sales by 9 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$19.8 M
17 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (44)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Michael J. DeppeSVP, Corp. Controller & CAO | 35,203 | — | $3.1 M | |
| Patrick PlewmanSVP for Diagnostic Services | 14,684 | — | $5.0 M | |
| Catherine T. DohertyExecutive Vice President | 71,949 | — | $12.4 M | |
| Mark E. DelaneySVP & Chief Commercial Officer | 12,975 | — | $376 K | |
| Subu RamachandranSVP, Regional Businesses | 2,832 | — | — | |
| Gary M. PfeifferDirector | 29,802 | — | $292 K | |
| Karthik KuppusamySVP, Clinical Solutions | 13,619 | — | $2.2 M | |
| Robert B. CarterDirector | 3,874 | — | — | |
| Sam SamadExecutive Vice President & CFO | 33,568 | — | — | |
| Timothy L. MainDirector | 22,478 | — | — | |
| Vicky B. GreggDirector | 18,449 | — | $240 K | |
| Wright Lassiter IIIDirector | 10,329 | — | — | |
| J. E. DavisCEO and President, Director | 122,423 | — | $17.1 M | |
| Michael E. PrevoznikSVP & General Counsel | 36,557 | — | $6.6 M | |
| Denise M. MorrisonDirector | 11,929 | — | — | |
| Luis DiazDirector | 5,196 | — | — | |
| Timothy C. WentworthDirector | 1,358 | — | — | |
| Timothy M. RingDirector | 31,140 | — | — | |
| Tracey DoiDirector | 7,748 | — | — | |
| Mark A. GardnerSVP of Molecular Gen & Oncol | 4,673 | — | — | |
| Gail R. WilenskyDirector | 20,506 | — | — | |
| Stephen H. RusckowskiDirector | 389,597 | — | — | |
| Manner Carrie EglintonSVP, Advanced Diagnostics | 48,391 | — | — | |
| Mark GuinanExecutive Vice President & CFO | 98,981 | — | — | |
| Helen TorleyDirector | 6,260 | — | — | |
| Manuel O. MendezSVP & Chief Commercial Officer | 29,045 | — | — | |
| Daniel StanzioneDirector | 28,349 | — | — | |
| Everett CunninghamSVP, Commercial | 38,311 | — | — | |
| Robert A. KlugVP, Corporate Controller | 6,261 | — | — | |
| Jenne K. BritellDirector | 17,660 | — | — | |
| Jeffrey M. LeidenDirector | 6,000 | — | — | |
| Jon R. CohenSVP & Group Exec. Diag. Sol. | 31,757 | — | — | |
| John B. ZieglerDirector | 16,557 | — | — | |
| John C. BaldwinDirector | 12,949 | — | — | |
| Thomas F. BongiornoVP and Corporate Controller | 11,837 | — | — | |
| John B. HaydonSVP, Operations | 19,890 | — | — | |
| William F. BuehlerDirector | 26,225 | — | — | |
| Kathy OrdonezSVP, Diagnostic Solutions | 9,569 | — | — | |
| Robert HagemannSVP & Chief Financial Officer | 126,722 | — | — | |
| Surya N. MohapatraChairman, President & CEO, Director | 243,713 | — | — | |
| Joan Elizabeth MillerSVP-Oncology & Neurology Srvcs | 89,232 | — | — | |
| Wayne R. SimmonsVice President, Operations | 47,150 | — | — | |
| Glaxosmithkline PLCDirector, 10% owner | — | — | — | |
| Rosanne HaggertyDirector | 9,334 | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark GuinanSenior Vice President & CFO | Buy | +4,000 | $55.51 | $222 K | 44,222 | Form 4 |
| filed | Timothy L. MainDirector | Buy | +2,400 | $50.70 | $122 K | 3,058 | Form 4 |
| filed | Timothy L. MainDirector | Buy | +2,600 | $50.71 | $132 K | 5,658 | Form 4 |
| filed | Stephen H. RusckowskiPresident and CEO, Director | Buy | +5,000 | $59.34 | $297 K | 68,034 | Form 4 |
| filed | Stephen H. RusckowskiPresident and CEO, Director | Buy | +20,000 | $56.89 | $1.1 M | 63,034 | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice